Terumo To Start U.S. Stent Trials
This article was originally published in PharmAsia News
Executive Summary
Major Japanese medical device maker Terumo will start clinical trials for Misago, a peripheral self-expanding stent indicated for femoral and popliteal artery disease in the U.S and Japan within the year. The company launched the product in Europe aiming for ¥10 billion in annual sales. Last year, Terumo opened a Swiss location for the launch of Nobori, a new generation of drug-eluting stent used in patients suffering from coronary artery disease, and Misago. (Click here for more - Japanese language